Nirmatrelvir-ritonavir may lower risk of intubation or in-hospital mortality in patients with severe COVID-19.

We conducted a phase 2–3 double-blind trial to assess the efficacy and safety of nirmatrelvir–ritonavir in asymptomatic, rapid antigen test–negative adults who had been exposed to a household contact ...

Editor's note: Find the latest COVID-19 news and guidance in Medscape's Coronavirus Resource Center. Nirmatrelvir–ritonavir (Paxlovid) is associated with a reduced risk for death or hospitalization in ...

Protease inhibitors were the original linchpins of highly active antiretroviral therapy (HAART) and proved to be epic lifesavers. But a shadow fell over them with the growing awareness of their ...

Ongoing clinical results with ratutrelvir confirm a differentiated profile versus PAXLOVID® with fewer adverse events, no ...